The measurement of efficacy in the drug discovery agonist selection process

被引：10

作者：

Kenakin, T ^{[1
]}

机构：

[1] Glaxo Wellcome Inc, Res & Dev, Dept Receptor Biochem, Res Triangle Pk, NC 27709 USA

来源：

关键词：

D O I：

10.1016/S1056-8719(00)00070-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：177 / 187

页数：11

共 15 条

[1] OPERATIONAL MODELS OF PHARMACOLOGICAL AGONISM [J].

BLACK, JW ;

LEFF, P .

PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1983, 220 (1219) :141-162

[2]

CLARK AJ, 1933, MODEL ACTION DRUGS C

[3]

Clark AJ, 1937, HEFFNERS HDB EXPT PH, V4

[4] The elusive nature of intrinsic efficacy [J].

Clarke, WP ;

Bond, RA .

[5] IMPRECISION IN PRESENTATION OF BINDING-STUDIES [J].

COLQUHOUN, D .

[6]

COLQUHOUN D, 1987, PERSPECTIVES RECEPTO, P103

[7]

Furchgott R., 1966, ADV DRUG RES, V3, P21

Kenakin, T .

[9]

Kenakin T., 1997, Pharmacologic analysis of drug-receptor interaction, Vthird

[10]

KENAKIN TP, 1980, J PHARMACOL EXP THER, V213, P406